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Purpose. The aim of this study is to describe compliance, acute toxicity and radiochemotherapy treatment outcomes in patients
diagnosed with locally advanced squamous cell carcinoma of head and neck.
Patients and methods. From March 2002 to January 2012, 942 patients diagnosed with head and neck cancer were treated in our
department. A subgroupof 150 patients received chemoradiation therapywith radical intent. The radiotherapy schedule usedwas
50Gy to clinical target volume (CTV) and 70Gy to the gross target volume (GTV). The concomitant chemotherapy (QT) regimens
were adapted to each clinical case.
Results. The median age was 61 years (range 39–82), 87% male and 13% female. 27% of all patients were stage III and 67% stage
IV. Locations: 62 larynx (42%), oropharynx 44 (29%), oral cavity 20 (13%), hypopharynx 24 (16%). 77% of all patients received
concomitant QT according to the following schemes: 60% received weekly CDDP, 20% CDDP every 21 days, 15% Carboplatin,
Cetuximab 5% and the remaining patients received others regimens. G3 toxicity was seen in 35% of patients and mucositis and
epithelitis were the most frequent. Median follow-up was 33 months (range 4–115). Two-year and ﬁve-year overall survival (OS),
cause-speciﬁc survival (CSS) and disease-free survival (DFS) were 62% and 37%, 66% and 60%, 64% and 43%, respectively. There
was not signiﬁcant difference in survival with the following analyzed variables: location, sex, age and QT scheme.
Conclusions. In our series conservative treatment with radiochemotherapy in locally advanced head and neck cancer offers a good
toxicity proﬁle and results comparable to those published in the literature.
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Purpose/objectives. To evaluate survival and toxicity of re-irradiation (re-RT) in head and neck cancer.
Materials/methods. Retrospective review of patients (n=29) treated with curative (n=25) or palliative (n=4) re-RT for recurrent
(n=24) or second primary (n=5) tumors of any histology (23 squamous, 2 adenocarcinomas, 3 undifferentiated and 1 con-
drosarcoma) between 2002 and 2011. Locations included: oropharynx/oral cavity (14), hipopharynx/larynx (5), nasopharynx (6),
nose/paranasal sinuses (3) and parotid (1). Re-RT considered as any overlap between original and new radiotherapy (RT) volumes.
Radiation-related toxicities scored using RTOG criteria. Median interval between RT treatments was 26 months (4–133). Salvage
surgery preceded re-RT in 12 patients; 24 patients received concurrent chemotherapy and/or cetuximab. Re-RT was given with
step-and-shot IMRT (n=23), 3D conformal RT (n=4), radiosurgery (n=1) or brachytherapy (n=1). Median cumulative, prior RT and
re-RT doses were 123.5Gy (84–153), 66Gy (59–83) and 50Gy (14–70) respectively. Univariate analysis was performed using the log
rank test. Survival was calculated with Kaplan–Meier method.
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